Genomic and clinicopathological features of lung adenocarcinomas with micropapillary component
BackgroundLung adenocarcinoma (LA) with a micropapillary component (LAMPC) is a histological subtype of lung cancer that has received increasing attention due to its correlation with poor prognosis, and its tendency to recur and metastasize. At present, comprehensive genomic profiles and clinicopath...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.989349/full |
| _version_ | 1828093610082435072 |
|---|---|
| author | Peng Li Lu Liu Dong Wang Ronghua Yang Yunpeng Xuan Yudong Han Jinglong Wang Lijie Guo Liwen Zhang Shanshan Zhang Yongjie Wang |
| author_facet | Peng Li Lu Liu Dong Wang Ronghua Yang Yunpeng Xuan Yudong Han Jinglong Wang Lijie Guo Liwen Zhang Shanshan Zhang Yongjie Wang |
| author_sort | Peng Li |
| collection | DOAJ |
| description | BackgroundLung adenocarcinoma (LA) with a micropapillary component (LAMPC) is a histological subtype of lung cancer that has received increasing attention due to its correlation with poor prognosis, and its tendency to recur and metastasize. At present, comprehensive genomic profiles and clinicopathological features for LAMPC remain unclear and require further investigation.MethodsFrom September 2009 to October 2020, a total of 465 LAMPC patients were recruited and divided into four groups according to MPC proportions, and the correlations between varying proportions of MPCs and clinicopathological characteristics were analyzed. Twenty-nine (29) LAMPC patients and 89 LA patients without MPC (non-MPC) that had undergone NGS testing were selected for further study The comprehensively analyze genomic variations and the difference between LAMPC and MPC were determined. In addition, Gene alterations of LAMPC between Chinese and Western populations were also compared using cBioPortal data.ResultsA higher proportion of MPCs, associated with higher tumor stage, pleural invasion, and vascular tumor thrombus formation, was determined in LA patients. Compared to non-MPC patients, LAMPC patients were determined to have a lower frequency of single nucleotide variants and a higher frequency of insertion-deletion mutations. Mutations in TP53, CTNNB1, and SMAD4, and ALK rearrangements/fusions were significantly more frequent in LAMPC patients. ERBB2 mutations were only detected in non-MPC patients. Gene mutations in the Wnt pathway were significantly more common in LAMPC patients as compared to non-MPC patients. ALK fusions were more prevalent in younger patients. Patients with KRAS or LBP1B mutations had significantly larger tumor diameters than patients with wild-type KRAS or LBP1B. Patients with KRAS mutations were more likely to develop vascular tumor thrombus. Using the cBioPortal public database, we determined that mutations in EGFR were significantly higher in Chinese patients than in a Memorial Sloan Kettering Cancer Center (MSKCC) Western cohort. ALK fusions were exclusively detected in the Chinese cohort, while mutations in KEAP1 and NOTCH4 were only detected in the MSKCC cohort. Our analysis of signaling pathways revealed that Wnt pathway gene mutations were significantly higher in the Chinese cohort.ConclusionLA patients with higher proportions of MPCs were determined to have a higher tumor stage, pleural invasion, and vascular tumor thrombosis formation. We comprehensively analyzed the genomic mutation characteristics of LAMPC patients and identified multiple, novel MPC-related gene alterations and pathway changes. Our data provide further understanding of the nature of the LAMPC and potential drug-targeted gene alterations, which may lead to new therapeutic strategies. |
| first_indexed | 2024-04-11T06:46:27Z |
| format | Article |
| id | doaj.art-ffc108865b924c09bc87f524070ffe73 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T06:46:27Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-ffc108865b924c09bc87f524070ffe732022-12-22T04:39:20ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-11-011210.3389/fonc.2022.989349989349Genomic and clinicopathological features of lung adenocarcinomas with micropapillary componentPeng Li0Lu Liu1Dong Wang2Ronghua Yang3Yunpeng Xuan4Yudong Han5Jinglong Wang6Lijie Guo7Liwen Zhang8Shanshan Zhang9Yongjie Wang10Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, ChinaDepartment of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, ChinaDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, ChinaDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, ChinaDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, ChinaDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, ChinaDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, ChinaMedical Department, OrigiMed Co., Ltd, Shanghai, ChinaMedical Department, OrigiMed Co., Ltd, Shanghai, ChinaMedical Department, OrigiMed Co., Ltd, Shanghai, ChinaDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, ChinaBackgroundLung adenocarcinoma (LA) with a micropapillary component (LAMPC) is a histological subtype of lung cancer that has received increasing attention due to its correlation with poor prognosis, and its tendency to recur and metastasize. At present, comprehensive genomic profiles and clinicopathological features for LAMPC remain unclear and require further investigation.MethodsFrom September 2009 to October 2020, a total of 465 LAMPC patients were recruited and divided into four groups according to MPC proportions, and the correlations between varying proportions of MPCs and clinicopathological characteristics were analyzed. Twenty-nine (29) LAMPC patients and 89 LA patients without MPC (non-MPC) that had undergone NGS testing were selected for further study The comprehensively analyze genomic variations and the difference between LAMPC and MPC were determined. In addition, Gene alterations of LAMPC between Chinese and Western populations were also compared using cBioPortal data.ResultsA higher proportion of MPCs, associated with higher tumor stage, pleural invasion, and vascular tumor thrombus formation, was determined in LA patients. Compared to non-MPC patients, LAMPC patients were determined to have a lower frequency of single nucleotide variants and a higher frequency of insertion-deletion mutations. Mutations in TP53, CTNNB1, and SMAD4, and ALK rearrangements/fusions were significantly more frequent in LAMPC patients. ERBB2 mutations were only detected in non-MPC patients. Gene mutations in the Wnt pathway were significantly more common in LAMPC patients as compared to non-MPC patients. ALK fusions were more prevalent in younger patients. Patients with KRAS or LBP1B mutations had significantly larger tumor diameters than patients with wild-type KRAS or LBP1B. Patients with KRAS mutations were more likely to develop vascular tumor thrombus. Using the cBioPortal public database, we determined that mutations in EGFR were significantly higher in Chinese patients than in a Memorial Sloan Kettering Cancer Center (MSKCC) Western cohort. ALK fusions were exclusively detected in the Chinese cohort, while mutations in KEAP1 and NOTCH4 were only detected in the MSKCC cohort. Our analysis of signaling pathways revealed that Wnt pathway gene mutations were significantly higher in the Chinese cohort.ConclusionLA patients with higher proportions of MPCs were determined to have a higher tumor stage, pleural invasion, and vascular tumor thrombosis formation. We comprehensively analyzed the genomic mutation characteristics of LAMPC patients and identified multiple, novel MPC-related gene alterations and pathway changes. Our data provide further understanding of the nature of the LAMPC and potential drug-targeted gene alterations, which may lead to new therapeutic strategies.https://www.frontiersin.org/articles/10.3389/fonc.2022.989349/fulllung adenocarcinomamicropapillary componentnext-generation sequencingclinicopathological featuresprognosis |
| spellingShingle | Peng Li Lu Liu Dong Wang Ronghua Yang Yunpeng Xuan Yudong Han Jinglong Wang Lijie Guo Liwen Zhang Shanshan Zhang Yongjie Wang Genomic and clinicopathological features of lung adenocarcinomas with micropapillary component Frontiers in Oncology lung adenocarcinoma micropapillary component next-generation sequencing clinicopathological features prognosis |
| title | Genomic and clinicopathological features of lung adenocarcinomas with micropapillary component |
| title_full | Genomic and clinicopathological features of lung adenocarcinomas with micropapillary component |
| title_fullStr | Genomic and clinicopathological features of lung adenocarcinomas with micropapillary component |
| title_full_unstemmed | Genomic and clinicopathological features of lung adenocarcinomas with micropapillary component |
| title_short | Genomic and clinicopathological features of lung adenocarcinomas with micropapillary component |
| title_sort | genomic and clinicopathological features of lung adenocarcinomas with micropapillary component |
| topic | lung adenocarcinoma micropapillary component next-generation sequencing clinicopathological features prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.989349/full |
| work_keys_str_mv | AT pengli genomicandclinicopathologicalfeaturesoflungadenocarcinomaswithmicropapillarycomponent AT luliu genomicandclinicopathologicalfeaturesoflungadenocarcinomaswithmicropapillarycomponent AT dongwang genomicandclinicopathologicalfeaturesoflungadenocarcinomaswithmicropapillarycomponent AT ronghuayang genomicandclinicopathologicalfeaturesoflungadenocarcinomaswithmicropapillarycomponent AT yunpengxuan genomicandclinicopathologicalfeaturesoflungadenocarcinomaswithmicropapillarycomponent AT yudonghan genomicandclinicopathologicalfeaturesoflungadenocarcinomaswithmicropapillarycomponent AT jinglongwang genomicandclinicopathologicalfeaturesoflungadenocarcinomaswithmicropapillarycomponent AT lijieguo genomicandclinicopathologicalfeaturesoflungadenocarcinomaswithmicropapillarycomponent AT liwenzhang genomicandclinicopathologicalfeaturesoflungadenocarcinomaswithmicropapillarycomponent AT shanshanzhang genomicandclinicopathologicalfeaturesoflungadenocarcinomaswithmicropapillarycomponent AT yongjiewang genomicandclinicopathologicalfeaturesoflungadenocarcinomaswithmicropapillarycomponent |